Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Andres

Pain Medicine Elizabethtown, KY Medical Doctor

NPI 1033564166 CMS profile 5704173

2407 Ring Rd Ste 135, Elizabethtown, KY 42701

Open in the dashboard

General payments

$11,222

288 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Andres of Elizabethtown, KY is reported in the CMS Open Payments database as having received $11,222 across 288 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,750 56
2024 General $3,200 86
2023 General $1,582 56
2022 General $3,970 71
2021 General $697 18
2019 General $23 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Andres
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Kevin Andres were reported at $1,750. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Kevin Andres Pain Medicine median Middle half National median
2019 $23 $409 $115–$1,311 $163
2020 $0 $214 $66–$666 $114
2021 $697 $299 $84–$899 $132
2022 $3,970 $335 $103–$1,149 $149
2023 $1,582 $376 $114–$1,228 $160
2024 $3,200 $387 $115–$1,173 $164
2025 $1,750 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,724 58 payments
  2. Boston Scientific Corporation $2,258 34 payments
  3. Spinal Simplicity, LLC $1,573 13 payments
  4. Saluda Medical Americas, Inc. $1,091 39 payments
  5. Abbott Laboratories $719 14 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $551 44 payments
  7. Nevro Corp. $384 9 payments
  8. Collegium Pharmaceutical, Inc. $384 22 payments
  9. SI-BONE, Inc. $311 8 payments
  10. MML US, Inc. $238 5 payments
  11. Other $989 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,596 268 payments
  2. Travel and Lodging $3,600 18 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25 1 payment
  4. Gift $0 1 payment
Products named General payments · program years 2019–2025
  1. HA MINUTEMAN G3-R $1,573 13 payments
  2. Superion Indirect Decompression System $1,417 9 payments
  3. KYPHON EXPRESS II KYPHOPAK TRAY $1,344 13 payments
  4. INTELLIS ADAPTIVESTIM $1,012 26 payments
  5. Evoke $787 33 payments
  6. RELISTOR $488 41 payments
  7. Proclaim IPG $307 6 payments
  8. Evoke SCS $304 6 payments
  9. WaveWriter Alpha Prime 16 $302 12 payments
  10. PROCLAIM $287 6 payments
  11. Other $2,862 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

9,185

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$322,178

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

50.9%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 3,547 $102,236
Oxycontin Oxycodone Hcl Brand 68 $39,874
Oxycodone Hcl Generic 830 $21,890
Xtampza Er Oxycodone Myristate Brand 22 $21,387
Pregabalin Generic 491 $18,464
Gabapentin Generic 1,668 $17,121
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 778 $17,054
Nucynta Tapentadol Hcl Brand 21 $16,840
Movantik Naloxegol Oxalate Brand 31 $14,388
Ztlido Lidocaine Brand 12 $13,724

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$501,153

Of which drugs: $172

Medicare patients

732

Average age 67

Services billed

9,724

448 women, 284 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 42%
Diabetes 38%
COPD 32%
Ischemic heart disease 28%
Chronic kidney disease 22%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 88 1,210 $103
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 66 244 $67

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $122
$122 22 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $54
$54 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $45
$45 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

288 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record